Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
NCT Number: NCT02460237
This study will pilot test a culturally appropriate human papillomavirus (HPV) self-test intervention among women from Ohio Appalachia in order to determine the feasibility of HPV self-testing as a potential cervical cancer screening strategy. The intervention group will receive culturally appropriate materials and the control group will receive standard materials with their HPV self-test device.
Looking for future studies?
Notify Me30 year–65 year
Female
Interventional
Not applicable
Columbus, Ohio, 43210, United States
PRIMARY OBJECTIVES:
I. To determine the feasibility of HPV self-testing as a potential cervical cancer screening strategy and obtain preliminary efficacy data of culturally appropriate materials on self-test use.
OUTLINE:
Participants are randomized to 1 of 2 arms.
ARM I: Participants receive a study kit that includes culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing. Participants are asked to complete the HPV self-test and return the test for HPV testing.
ARM II: Participants receive a study kit that includes standard instructions for using and returning the HPV self-test device and a standard information sheet about HPV and cervical cancer. Participants are asked to complete the HPV self-test and return the test for HPV testing.
Participants are followed up at 4 weeks for return of their HPV self-test device and then for 2 months after notification letters are sent.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Complete HPV self-test
Other names: Disease Screening Procedure, Screening, Screening Intervention
Receive culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing
Other names: Education for Intervention, Intervention, Educational
Receive standard instructions and information sheet
Correlative studies
Ancillary studies
Time frame: Up to 4 weeks from kit distribution
A chi-square test will be used to test for a difference between the two groups.
Time frame: Up to 2 months after notification letters are sent
Descriptive statistics (e.g., proportions) will be calculated for the entire sample and by study arm.
Time frame: After shipping the specimen, an expected average of 6 weeks
Descriptive statistics (e.g., proportions) will be calculated for the entire sample and by study arm.
Time frame: After shipping the specimen, an expected average of 6 weeks
Descriptive statistics (e.g., proportions) will be calculated for the entire sample and by study arm.
Time frame: Up to 2 months after receiving notification letters are sent
Descriptive statistics (e.g., proportions) will be calculated for the entire sample and by study arm.
Ohio State University Comprehensive Cancer Center
Other
Pilot Testing an HPV Self-Test Intervention: A Novel Strategy for Reducing Cervical Cancer in Appalachia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04411849
Cervical Carcinoma, Communicable Diseases
Lexington, Kentucky, United States
View Trial DetailsNCT05458869
Cervical Carcinoma, Communicable Diseases
Portland, Oregon, United States
View Trial DetailsNCT02355262
Breast Carcinoma, Breast Diseases
Portland, Oregon, United States
View Trial DetailsNCT01550783
Atypical Squamous Cell of Undetermined Significance, Atypical Squamous Cells of the Cervix
Minneapolis, Minnesota, United States
View Trial Details